Internal Medicine

Clinical trials for Internal Medicine specialty

  • Status:  Currently enrolling

    Description:

    The purpose of the study is to investigate ways to monitor dogs that have been diagnosed with chronic inflammation in their liver so called chronic hepatitis in dogs. We are performing this study to evaluate whether these blood tests correlate with the severity of the dog’s liver disease.

    Inclusion Criteria:

    • Dogs weighing greater than 6 kg (13 lbs)
    • Dogs with histologically confirmed chronic hepatitis

    Exclusion Criteria:

    • history of use of corticosteroids, ursodeoxycholate, NSAIDs, omega-3 or vitamin D supplementation within 2 weeks of enrollment or the use of DDAVP within 24 hours
    • degenerative mitral valve disease, renal disease (Creat >2.0 mg/dL), concurrent active infection, neoplasia, IBD, immune mediated hemolytic anema, pnacreatitis or immune mediated polyarthropathy

    Client Benefits:

    The study will cover the costs of the vitamin D, CRP and von Willebrand factors as well as a complete blood count and serum chemistry at the first recheck appointment.

    Contact information:

    For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at:  clinicaltrials@tufts.edu

     

     

     

  • CSRC protocol #: G2016.33

    Status:  Currently enrolling

    Description:

    To determine if telmisartan, a medication used to reduce protein loss through the kidneys, is broken down and processed differently in dogs with kidney disease compared to healthy dogs.

    To compare the ability of telmisartan to control protein loss through the kidneys in dogs with protein-losing kidney disease (protein-losing nephropathy, or PLN) with benazepril, one of the medications in the class of medications (angiotensin-converting enzyme inhibitors) that is currently standard therapy for this disease.

    We hypothesize that the processing of telmisartan in dogs with PLN will be altered compared to the patterns previously established in healthy dogs, and that telmisartan will be equally or more effective than benazepril at treating PLN.

    This study serves to evaluate telmisartan, a medication commonly used in human medicine, for its role in helping to treat protein-losing nephropathy, a potentially devastating disease in dogs.  If successful, this may open a new option for treatment of dogs with PLN who don’t respond to standard therapies, such as benazepril.  In addition, the pharmacokinetics of telmisartan (or any angiotensin-receptor blocker) in dogs with PLN has not been previously evaluated.

    Inclusion Criteria:

    Dogs who have been diagnosed with protein-losing nephropathy (as defined by having a urine protein:creatinine ratio >2.0 with no evidence of non-renal causes of proteinuria).

    Client benefits:

    The direct benefit from this study for your dog is that he or she will receive one of two promising therapies for protein-losing kidney disease with close monitoring of his or her response to therapy.  The direct benefit to you is that the costs of either medication (benazepril or losartan) will be covered for the duration of the study (6 months).  You will be responsible for the costs of the preliminary diagnostic tests (including ultrasound) and the costs of the recheck appointments and urine and blood testing at these rechecks.

    Contact information:

    For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at:  clinicaltrials@tufts.edu

     

     

  • Status:  Currently enrolling

    Description:

    We hypothesize that the orally administered drug, bexagliflozin, will improve glycemic control in poorly regulated diabetic cats. The primary objective of this study is to determine if mean blood sugar and fructosamine concentrations decrease by ≥10% with administration of bexagliflozin over a two week period. The secondary objective is to determine if bexagliflozin is well tolerated by poorly regulated diabetic cats.

    Inclusion Criteria:

    Cats with unregulated diabetes mellitus based on history of persistent hyperglycemia(>250 mg/dl) and appropriate clinical signs, including polyuria, polydipsia and weight loss

    Exclusion Criteria:

    Cats with documented azotemia, elevated bilirubin, ALT >2.5x the upper limit of normal, diabetic ketoacidosis, urinary tract infection, use of corticosteroids within the past 8 weeks, heart disease requiring medication and uncontrolled hyperthyroidism based on preliminary laboratory testing

    Client benefits:

    The study will cover the costs of blood work and urine tests required for the study, blood pressure measurement, day boarding as well as the cost of the medication.  We will be teaching you how to monitor your cat's blood glucose levels at home with a hand held glucometer that will be loaned from our hospital for the duration of the study.

    Contact information:

    For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at: clinicaltrials@tufts.edu

  • CSRC protocol # 003.17

    Status:  Currently enrolling

    Description:

    Gallbladder mucoceles (GBM) are a common and significant cause of biliary disease in dogs.  We hypothesize that dogs with GBM will have coagulation parameters compatible with a hypercoagulable state. We hope to determine if there is a correlation between these coagulation parameters and known risk factors for mortality in dogs undergoing cholecystectomy for GBM, clinical course and ultrasonographic findings associated with gallbladder rupture.

    Inclusion criteria:

    • Ultrasonographically diagnosed gallbladder mucocele (GBM).
    • Dogs must have had a complete blood count, chemistry and urinalysis within 24 hours of the ultrasound diagnosis
    • Body weight greater than 5 kg

    Exclusion criteria:

    • Administration of vitamin K, blood productions or any other medications known to affect coagulation (nonsteroidal anti-inflammatory medications, corticosteroids, heparin, clopidogrel, free fatty acids or hydroxylethyl starch) within 2 weeks of the sample collection
    • Greyhounds will be excluded

    Client Benefits:

    The study will cover the costs of coagulation testing (prothrombin time, partial thromboplastin time, factor VIII activity, fibrinogen, Ddimer, thromboelastrography, protein C activ ity, antithrombin activity and von willebrand factor activity). We will share the results of the thromboelastography with you. The other coagulation tests will not be performed immediately. Your pet's participation will also allow us to gain information regarding the coagulation status in dogs with gallbladder mucoceles which may help in the management of other dogs with this condition. You understand that your animal's participation in this study may not alleviate or cure his/her ailment.

    Contact information:

    For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at:  clinicaltrials@tufts.edu

     

     

     

  • IACUC Protocol # G2016-161

    Status: Currently enrolling

    Description:

    To develop tests to measure lymphocyte function in healthy animals, which will then be able to be used to monitor disease in sick dogs and rabbits. Lymphocytes are a type of white blood cells that function as part of the immune system. Normally, they respond properly to foreign invaders in the body. When the lymphocytes do not act properly diseases may occur.

    Once adequately developed and validated, the proposed tests will allow us to evaluate immune function in dogs and rabbits with diseases affecting their immune systems. The various applications of these tests include evaluating rabbits with Encephalitozoon cuniculi, an infection also affecting humans, and measuring the effects of immune suppressing drugs taken by both dogs and humans.  To be able to measure immune responses in sick patients, we must first develop the tests in blood from healthy animals.

    Inclusion Criteria:

    Healthy dogs weighing more than 5 kg and between the ages of 1 and 12

    Healthy rabbits weighing more than 1 kg and between the ages of 1 and 6

    Exclusion criteria:

    Dogs: weighing < 5 kg

    < 1 year old or > 12 years old

    Pregnant

    Rabbits: weighing < 1 kg

    < 1 year old or > 6 years old

    Pregnant

    Contact information:

    For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at:  clinicaltrials@tufts.edu

     

  • IACUC protocol #: G2017-28

    Status:  Currently enrolling

    Description:

    Immune-mediated hemolytic anemia (IMHA) is an important disease in dogs that causes anemia (a low red blood cell count). We would like to be able to identify how a patient is responding to therapy using a blood test.  We hope to identify how long it takes to see suppression of the immune markers in a blood sample during therapy and see if this varies by treatment regimen used.  We will be looking at three different  lymphocyte responses during treatment for IMHA. Our goal is to identify if one of these markers decreases more rapidly in response to immunosuppressive treatment, and if one treatment is best associated with patient survival at 1 month.

    Inclusion Criteria:

    Dogs diagnosed with immune-mediated hemolytic anemia weighing more than 6 kg.

    Client Benefits:

    As part of the study, you will receive a free 2 and 4 week recheck with our Internal Medicine service. Cost of the blood draw will be covered by the study, as will the cost of the recheck red blood cell test (PCV).

    Contact Information:

    For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at:  clinicaltrials@tufts.edu

     

  • Protocol# G2017.35

    Status: Currently enrolling

    Description:

    Acute kidney injury (AKI) is a serious state in dogs, cats as well as in humans that is underdiagnosed due to a lack of diagnostic tools. This study is designed to test whether newly developed biomarkers correlate with declined kidney function in dogs. We hope to find biomarkers that detects kidney injury at an earlier stage compared to the ones currently being used, thus helping us to identify and treat patients at an early stage in order to improve outcome.

    Inclusion criteria:

    • Dogs that are likely to develop an AKI due to e.g. intoxications, sepsis, heatstroke
    • Dogs that are acutely azotemic (have elevated BUN and creatinine values) due to e.g. leptospirosis, intoxications, pyelonephritis, sepsis, heatstroke
    • Body weight greater than 4.5 kg

    Exclusion criteria

    • A known history of kidney disease

    Client Benefits:

    The study will cover the costs of blood work, including complete blood count, chemistry and Snap 4DX plus (test for vector- borne diseases) and urinalysis for the first four days of hospitalization, then every second day until discharge from hospital. It will also include free control visits at 4 weeks and 3 months from discharge with the laboratory work listed above.

  • Status:  Currently enrolling

    Description:

    Poor control of the glucose levels in diabetic dogs can alter how the drugs behave in the body, which can result in drug toxicities. The changes in blood proteins caused by diabetes can significantly affect the disposition of the many protein-bound drugs used in diabetic patients. This study will explore a model that will allow identification of changes in protein binding that will improve the safety of giving different medications to diabetic patients. This study has the potential to help diabetic dogs to receive appropriate medical care and have a better quality of life.

    Inclusion Criteria:

    Well diabetic adult dogs that weigh at least 3 kg (6.6 lbs) of any age and breed will be included in the study.

    Exclusion Criteria:

    Sick dogs, those receiving drugs known to be highly protein bound, and hypoalbuminemic dogs will not be included in the study.

    Client Benefits:

    The study entails having 2-3 teaspoons (12-15 ml) of blood drawn from your dog.  As an incentive, the study will cover the cost of a blood chemistry profile that would be performed as part of your dog's visit.

    Contact Information:

    For questions regarding the clinical trial please email the clinical trials office: clinicaltrials@tufts.edu